Marshall Wace North America’s Blueprint Medicines BPMC Stock Holding History

Marshall Wace North America’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$42.1M	Buy	409,205 +386,792	+1,726%	+$36M	0.18%	125
2021 Q2	$1.97M	Buy	+22,413	New	+$2.05M	0.01%	809
2021 Q1	–	Sell	-4,970	Closed	-$557K	–	1516
2020 Q4	$557K	Buy	+4,970	New	+$524K	﹤0.01%	1068
2020 Q3	–	Sell	-11,481	Closed	-$896K	–	1222
2020 Q2	$896K	Sell	11,481 -24,545	-68%	-$1.66M	0.01%	786
2020 Q1	$2.11M	Buy	+36,026	New	+$2.32M	0.02%	470
2019 Q2	–	Sell	-263,648	Closed	-$21.1M	–	1184
2019 Q1	$21.1M	Buy	+263,648	New	+$19.5M	0.15%	140
2018 Q4	–	Sell	-29,868	Closed	-$2.33M	–	1478
2018 Q3	$2.33M	Buy	+29,868	New	+$2.08M	0.02%	463
2017 Q3	–	Sell	-24,515	Closed	-$1.25M	–	1267
2017 Q2	$1.25M	Buy	24,515 +9,582	+64%	+$407K	0.01%	866
2017 Q1	$597K	Buy	+14,933	New	+$535K	﹤0.01%	791

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Marshall Wace North America's BPMC Position: Q3 2021 in Review

Marshall Wace North America increased its Blueprint Medicines (BPMC) stake by 1,726% in Q3 2021, buying an estimated $36M and bringing the position to 409,205 shares worth $42.1M. The position accounts for 0.18% of the portfolio, ranked #125.

Marshall Wace North America first reported a position in BPMC in Q1 2017 and has held it in 9 quarters since. 288 funds tracked by Wall St. Rank hold BPMC as of Q3 2021.

Marshall Wace North America held 409,205 shares of Blueprint Medicines worth $42.1M as of Q3 2021.
Marshall Wace North America bought 386,792 Blueprint Medicines shares in Q3 2021, an estimated $36M.
Blueprint Medicines made up 0.18% of Marshall Wace North America's portfolio in Q3 2021, its #125 holding.
Marshall Wace North America first reported a position in Blueprint Medicines in Q1 2017 and has held it in 9 quarters since.
288 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.